Raymond James Maintains Outperform on Leap Therapeutics, Raises Price Target to $4
Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and raises the price target from $3 to $4.
45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets.
Why Are Leap Therapeutics Shares Trading Higher On Monday?
Leap Therapeutics Inc (NASDAQ:LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company’s presentation…
21 Stocks Moving in Monday’s Pre-Market Session
Gainers
Itamar Medical Ltd. (NASDAQ: ITMR) rose 43% to $29.52 in pre-market trading. Zoll Medical said it has signed an agreement to acquire Itamar Medical for $31 per ADS in cash.
Leap Therapeutics To Present New Data From DisTinGuish Study Of DKN-01 Plus Tislelizumab At ESMO 2021 Congress
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of